Hong Kong Stock Alert | 3D MEDICINES (01244) Surges Over 10% as Self-Developed Next-Generation Precision Nuclear Medicine Completes First Patient Dosing, Nuclear Medicine Market Shows Enormous Potential

Stock News

Sep 09

3D MEDICINES (01244) surged over 10%, gaining 13.96% to HKD 9.06 at the time of writing, with trading volume reaching HKD 17.59 million.

On the news front, 3D MEDICINES recently announced that the first radioconjugate drug (RDC) from its proprietary nuclear medicine platform, 177Lu-PSMA-3D1015 injection, has completed first patient dosing in an investigator-initiated trial (IIT). The study aims to evaluate the safety and preliminary efficacy of 3D1015 in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).

According to data from MEDraysintell, the global nuclear medicine market is projected to reach nearly $39 billion by 2032. The company stated that 177Lu-PSMA-3D1015 injection has the potential to become a "best-in-class" nuclear medicine product, ultimately providing safer and more effective treatment options for prostate cancer patients worldwide, while advancing China's nuclear medicine R&D capabilities toward international leading standards.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1104268280"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1104268280\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1104268280?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-09 14:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1104268280","market":"hk","top_or_hot":-1,"title":"Hong Kong Stock Alert | 3D MEDICINES (01244) Surges Over 10% as Self-Developed Next-Generation Precision Nuclear Medicine Completes First Patient Dosing, Nuclear Medicine Market Shows Enormous Potential","media":"Stock News","content":"<p>3D MEDICINES (01244) surged over 10%, gaining 13.96% to HKD 9.06 at the time of writing, with trading volume reaching HKD 17.59 million.</p>\n<p>On the news front, 3D MEDICINES recently announced that the first radioconjugate drug (RDC) from its proprietary nuclear medicine platform, 177Lu-PSMA-3D1015 injection, has completed first patient dosing in an investigator-initiated trial (IIT). The study aims to evaluate the safety and preliminary efficacy of 3D1015 in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).</p>\n<p>According to data from MEDraysintell, the global nuclear medicine market is projected to reach nearly $39 billion by 2032. The company stated that 177Lu-PSMA-3D1015 injection has the potential to become a \"best-in-class\" nuclear medicine product, ultimately providing safer and more effective treatment options for prostate cancer patients worldwide, while advancing China's nuclear medicine R&D capabilities toward international leading standards.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Alert | 3D MEDICINES (01244) Surges Over 10% as Self-Developed Next-Generation Precision Nuclear Medicine Completes First Patient Dosing, Nuclear Medicine Market Shows Enormous Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Alert | 3D MEDICINES (01244) Surges Over 10% as Self-Developed Next-Generation Precision Nuclear Medicine Completes First Patient Dosing, Nuclear Medicine Market Shows Enormous Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-09 14:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>3D MEDICINES (01244) surged over 10%, gaining 13.96% to HKD 9.06 at the time of writing, with trading volume reaching HKD 17.59 million.</p>\n<p>On the news front, 3D MEDICINES recently announced that the first radioconjugate drug (RDC) from its proprietary nuclear medicine platform, 177Lu-PSMA-3D1015 injection, has completed first patient dosing in an investigator-initiated trial (IIT). The study aims to evaluate the safety and preliminary efficacy of 3D1015 in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).</p>\n<p>According to data from MEDraysintell, the global nuclear medicine market is projected to reach nearly $39 billion by 2032. The company stated that 177Lu-PSMA-3D1015 injection has the potential to become a \"best-in-class\" nuclear medicine product, ultimately providing safer and more effective treatment options for prostate cancer patients worldwide, while advancing China's nuclear medicine R&D capabilities toward international leading standards.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01244","symbol_name":"思路迪医药股份","start_time":0,"source_url":"","article_id":"1104268280","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1104268280","pubTimestamp":1757397871,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"3D MEDICINES (01244) surged over 10%, gaining 13.96% to HKD 9.06 at the time of writing, with trading volume reaching HKD 17.59 million. On the news front, 3D MEDICINES recently announced that the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01244":"思路迪医药股份","BK1161":"生物科技"},"translate_title":"港股快讯|3D MEDICINES(01244)大涨超10%自研下一代精准核医学完成首例患者给药核医学市场展现巨大潜力","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01244":1},"content_text":"3D MEDICINES (01244) surged over 10%, gaining 13.96% to HKD 9.06 at the time of writing, with trading volume reaching HKD 17.59 million.\nOn the news front, 3D MEDICINES recently announced that the first radioconjugate drug (RDC) from its proprietary nuclear medicine platform, 177Lu-PSMA-3D1015 injection, has completed first patient dosing in an investigator-initiated trial (IIT). The study aims to evaluate the safety and preliminary efficacy of 3D1015 in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).\nAccording to data from MEDraysintell, the global nuclear medicine market is projected to reach nearly $39 billion by 2032. The company stated that 177Lu-PSMA-3D1015 injection has the potential to become a \"best-in-class\" nuclear medicine product, ultimately providing safer and more effective treatment options for prostate cancer patients worldwide, while advancing China's nuclear medicine R&D capabilities toward international leading standards.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}